The startup operates a biomedical tech platform that utilizes protein engineering, condensate biology, medicinal chemistry, and high-throughput microscopy screening to create biomolecular tools for therapeutic and synthetic biology applications. This platform enables researchers to develop targeted therapies for condensate-associated diseases and enhances the efficiency of synthetic biology research.
Funding
$3.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Cellular physiology and organization rely on membraneless organelles (MLOs), and dysfunctions associated with MLOs are implicated in various diseases, including neurodegenerative diseases, cancers, and viral infections. Understanding the biophysical mechanisms underlying the formation of MLOs, particularly liquid-liquid phase separation (LLPS) of biomolecules, is crucial for developing targeted therapies.
Solution
PartitionBio is developing biomolecular tools for therapeutic and synthetic biology applications, leveraging its expertise in protein engineering, condensate biology, medicinal chemistry, and high-throughput microscopy screening. The company's technology platform exploits LLPS-dependent biomolecular condensates (BMCs) to accelerate enzyme kinetics in _in vitro_ reaction systems and develop therapeutic solutions for condensate-associated diseases. PartitionBio aims to deploy its know-how and the emerging understanding of LLPS to develop innovative tools for synthetic biology applications and therapeutic solutions for condensate-associated diseases.
Target Audience
PartitionBio's primary customers are researchers and companies in the therapeutic and synthetic biology fields seeking innovative tools and solutions for condensate-associated diseases and enhanced synthetic biology research.
Features
- Proprietary technology platform focused on liquid-liquid phase separation (LLPS) of biomolecules.
- Expertise in protein engineering and condensate biology.
- Capabilities in medicinal chemistry and high-throughput microscopy screening.
- Development of biomolecular tools for therapeutic applications.
- Development of biomolecular tools for synthetic biology applications.
- Exploitation of LLPS-dependent biomolecular condensates (BMCs) to accelerate enzyme kinetics in _in vitro_ reaction systems.
- Focus on therapeutic solutions for condensate-associated diseases.
- Novel biologics shuttle platform for therapeutic nucleic acids delivery.